https://www.selleckchem.com/products/pu-h71.html
If treatment with single-dose azithromycin continues at current rates, macrolide-resistant M. genitalium infections will reach 25% (95% confidence interval, CI [9-30]%) in France, 84% (95% CI [36-98]%) in Denmark and 62% (95% CI [48-76]%) in Sweden by 2025. Conclusions Blind treatment of urethritis with single-dose azithromycin continues to select for the spread of macrolide resistant M. genitalium. Clinical management strategies for M. genitalium should limit the unnecessary use of macrolides. ©2020 Cadosch et al.Background Pancreatic c
Like
Comment
Share
